Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) PT at $7.67

Shares of Replimune Group, Inc. (NASDAQ:REPL) have earned an average rating of “Hold” from the twelve analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $7.6667.

Several equities research analysts have recently weighed in on the stock. Piper Sandler cut shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a research report on Tuesday, July 22nd. Leerink Partners restated a “market perform” rating and set a $3.00 target price (down previously from $21.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Leerink Partnrs cut Replimune Group from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 22nd. Cantor Fitzgerald raised Replimune Group from a “neutral” rating to an “overweight” rating in a research report on Wednesday, July 30th. Finally, HC Wainwright cut Replimune Group from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 23rd.

Insider Activity at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,952 shares of the firm’s stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $64,093.12. Following the completion of the sale, the insider owned 146,933 shares of the company’s stock, valued at approximately $1,184,279.98. This trade represents a 5.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Philip Astley-Sparke sold 32,279 shares of the business’s stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $260,168.74. Following the sale, the director owned 1,405,071 shares in the company, valued at $11,324,872.26. The trade was a 2.25% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock worth $603,655 over the last ninety days. Corporate insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC grew its holdings in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after buying an additional 1,655 shares during the last quarter. Graham Capital Management L.P. lifted its position in Replimune Group by 6.1% during the 4th quarter. Graham Capital Management L.P. now owns 30,180 shares of the company’s stock worth $365,000 after acquiring an additional 1,731 shares during the period. BNP Paribas Financial Markets grew its stake in Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after purchasing an additional 1,879 shares during the last quarter. Deutsche Bank AG grew its stake in Replimune Group by 0.4% during the 1st quarter. Deutsche Bank AG now owns 563,701 shares of the company’s stock valued at $5,496,000 after purchasing an additional 2,140 shares during the last quarter. Finally, MetLife Investment Management LLC increased its holdings in shares of Replimune Group by 7.2% in the fourth quarter. MetLife Investment Management LLC now owns 37,659 shares of the company’s stock valued at $456,000 after purchasing an additional 2,525 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Trading Up 3.9%

Shares of REPL opened at $5.56 on Thursday. Replimune Group has a twelve month low of $2.68 and a twelve month high of $17.00. The company’s fifty day simple moving average is $8.24 and its 200-day simple moving average is $9.57. The company has a market cap of $434.01 million, a P/E ratio of -1.72 and a beta of 0.67. The company has a current ratio of 6.94, a quick ratio of 7.95 and a debt-to-equity ratio of 0.21.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). As a group, analysts expect that Replimune Group will post -2.97 EPS for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.